News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Collegium Pharmaceutical, Inc. - Common Stock
(NQ:
COLL
)
35.20
-0.39 (-1.10%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 24, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Collegium Pharmaceutical, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Collegium to Report First Quarter 2025 Financial Results on May 8, 2025
April 24, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
2 Reasons to Watch COLL and 1 to Stay Cautious
April 14, 2025
Collegium Pharmaceutical’s stock price has taken a beating over the past six months, shedding 31.6% of its value and falling to $26.01 per share. This might have investors contemplating their next...
Via
StockStory
What Analysts Are Saying About Collegium Pharmaceutical Stock
↗
April 09, 2025
Via
Benzinga
A Look Back at Branded Pharmaceuticals Stocks’ Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack
April 02, 2025
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Collegium Pharmaceutical...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Earnings Scheduled For February 27, 2025
↗
February 27, 2025
Via
Benzinga
A Preview Of Collegium Pharmaceutical's Earnings
↗
November 06, 2024
Via
Benzinga
The Analyst Landscape: 4 Takes On Collegium Pharmaceutical
↗
September 05, 2024
Via
Benzinga
Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference
April 01, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine’s Annual Meeting
March 27, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
March 26, 2025
From
Avalo Therapeutics
Via
GlobeNewswire
Forecasting The Future: 4 Analyst Projections For Collegium Pharmaceutical
↗
March 24, 2025
Via
Benzinga
Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks
March 21, 2025
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Royalty Pharma (NASDAQ:RPRX)...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Collegium Announces Updates to its Board of Directors and Executive Leadership Team
March 17, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care
March 10, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Participate in Upcoming Investor Conferences
March 04, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Pharmaceutical’s (NASDAQ:COLL) Q4 Sales Top Estimates, Stock Jumps 14.1%
February 27, 2025
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 21.5% year on year to $181.9 million. The company...
Via
StockStory
Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results
February 27, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expect
February 26, 2025
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting earnings tomorrow after the bell. Here’s what to look for.
Via
StockStory
Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025
February 13, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Appoints Nancy S. Lurker to its Board of Directors
February 05, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium's Revenue Outlook And CNS Expansion Signal Undervalued Opportunity, Says Needham
↗
January 10, 2025
Needham analyst upgrades Collegium Pharmaceutical to Buy with a $46 target, citing strong 2025 guidance, growth potential, and undervaluation.
Via
Benzinga
Collegium Provides 2025 Financial Guidance and Business Update
January 08, 2025
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Participate in Upcoming Investor Conferences
November 12, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Reports Record Third Quarter 2024 Financial Results
November 07, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Appoints Vikram Karnani as Chief Executive Officer
November 07, 2024
Vikram Karnani is a Proven Industry Leader with Extensive Experience Growing Commercial Biopharmaceutical Businesses
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024
October 24, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
S&P Global To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Thursday
↗
September 05, 2024
Via
Benzinga
Topics
Stocks
Collegium Completes Acquisition of Ironshore Therapeutics
September 04, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Dr. Reddy's Stock Hit All-Time High Last Month. Ready To Climb Again?
↗
September 03, 2024
Dr. Reddy's Labs sees its Relative Strength Rating enter the 80-plus level.
Via
Investor's Business Daily
Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference
August 30, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
